Law Suits and Court Decisions Sep 15 2005: FDA Amicus Curiae–Kallas–claims FDA infallibility pre-empts state safety laws (warning: 1.6 MB file) Aug 6 2004: Psychiatrist Scolds the APA After Winning Distinguished Fellow Award/ NYC Sues 44 Pharma Companies Aug 5: Pfizer issues prosecutors a manual to defend drug – Star…
VIOXX – Merck–MEDCO – a case study Wed, 13 Oct 2004 Vioxx: A case study in how a lethal drug is marketed and dispensed – without MINIMAL safeguards to protect people’s lives. Merck marketed and sold billions of dollars worth of Vioxx through MEDCO–the largest Medicare Pharmacy Benefit Manager (PBM)…
NAMI & Eli Lilly partners in bankrupting state Medicaid budgets – NYT Sat, 20 Dec 2003 The New York Times reports that Medicaid expenditure for prescription drugs has escalated to $27.5 billion. These costs are up 19% from last year. Antipsychotic drugs, such as Eli Lilly’s Zyprexa, eat up more…
Infomail Archive 2003 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 19, 2003: Eli Lilly Prozac UK Fact Sheet: “Not Recommended” for Children – PMDD Withdrawn in UK Dec 19, 2003: Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry? Dec 18, 2003:…
Supreme Court Halts Forced Drugging – AAPS Press Release Mon, 16 Jun 2003 The Supreme Court rules against government efforts to force citizens to take mind-altering psychotropic drugs against their will. The 6 to 3 Supreme Court decision overturned lower district and appellate courts in the case of Dr. Charles…
THE ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) New York, NY 10023 212-595-8974 July 29, 2002 Greg Koski, MD, Ph.D. Office of the Secretary Office of Public Health and Science Office of Human Research Protection The Tower Building 1101 Wooten Parkway, Suite 200 Rockville, MD 20852 RELATED PAGES OHRP Investigation of…
REASONS FOR OPPOSITION:
Researchers would not be required to first try approved treatments, if any exist, before entering the patient into a medical experiment that may be "risky."
Researchers would not be required to consult with an independent medical expert, a non-researcher who would consider the patient’s best medical interests as paramount.
Researchers would not be required to disclose their own professional and financial interests deriving from the experiment.
Researchers would not be required to fully disclose to the patient’s family what happened to other patients who had already participated in the experiment.
